AEON Biopharma, Inc. (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under the 351(k) biosimilar pathway, today announced that its Board of Directors has approved…
© 2023 Copyright Futuresstocktrading.com – Futures Market, Investment, Trading & News